<DOC>
	<DOCNO>NCT02167217</DOCNO>
	<brief_summary>While know many year corticosteroid use benefit boy Duchenne Muscular dystrophy ( DMD ) , clinicians consider treat age 3 4 year age . The primary reason delay daily corticosteroid use many side effect include short stature , obesity , osteoporosis . A recent randomized blind study weekend oral corticosteroid use one year show equal improvement strength few side effect , particularly related growth cushingoid change . The investigator test efficacy oral weekend corticosteroid use infant young boy DMD age 30 month . The investigator demonstrate Bayley-III Scales Infant development show infant young boy age group untreated decline ability compare peer . Here , Phase 2 historically control trial , investigator use two measure treat boy five Muscular Dystrophy Association-DMD center</brief_summary>
	<brief_title>Historically Controlled Trial Corticosteroids Young Boys With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>Objective . Determine twice-weekly high dose oral prednisone improve gross motor development infant young boy DMD . The investigator perform phase 2 historically control trial oral twice-weekly prednisone ( 5mg/kg/dose two consecutive day ) infant young boy DMD . Here investigator propose study effect therapy multicenter trial boys DMD le 30 month old baseline visit . Each boy follow one year . Aim 1 . Determine treatment improve gross motor function infant DMD 6-12-month period measure Bayley-III . The Bayley-III infant score primary motor clinical endpoint therapeutic trial . Secondary outcome include fine motor function , speech language , social function . Aim 2 . Determine treatment improve Adaptive Behavior Subtest Bayley-III ( ABS ) score infant ' primary caregiver . In study untreated boy , primary caregiver note clear deficit , predominantly relate area relevant gross motor function . The ABS Aim 3 . Determine treatment improve performance NSAA boys ambulatory . Aim 4 . Determine treatment weekly corticosteroid tolerate safe boy DMD le 30 month age . Objective 2 . Determine ultrasound biceps quadriceps use calibrated backscatter improve infant young boy DMD treat oral high dose weekly corticosteroid . Preliminary data ultrasound imaging infant young boy DMD demonstrate progressive structural damage measure calibrated backscatter . The ultrasound study limit infant boys enroll primary site ( Washington University ) Dr. Craig Zaidman equipment expertise accomplish aim . Objective 3 . Determine caregiver burden change treatment infant young boy DMD . Preliminary data questionnaire suggest caregiver burden primary caregiver untreated infant young boy DMD minimal . Assessment trial allow u discern change therapeutic trial .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Appropriate degree weakness age , creatine kinase great 20 time upper limit normal , genetic mutation know causative Duchenne muscular dystrophy . 2 . Appropriate degree weakness age , creatine kinase great 20 time upper limit normal genetic biopsy confirmation Duchenne muscular dystrophy primary relative ( e.g . brother maternal uncle ) . 3 . Deidentified , genetic study review collaborator Kevin Flanigan prior enrollment subject . 4 . Age entry : one month 30 month . Prior treatment corticosteroid</criteria>
	<gender>Male</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>30 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>Infants</keyword>
	<keyword>Young Children</keyword>
	<keyword>Toddlers</keyword>
</DOC>